Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abatacept in ANCA-associated vasculitis
2008-004138-26Phase 2Terminated
- Sponsor
- Azienda Ospedaliero-Universitaria di Parma
- Start
- Jun 2008
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of abatacept in anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV), granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA) and 1 more, sponsored by Azienda Ospedaliero-Universitaria di Parma. Primary endpoint: Relapse rate after remission over 24 months. Started Jun 2008; status: terminated.
02
Drugs
abatacept
03
Conditions
anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV)granulomatosis with polyangiitis (GPA)microscopic polyangiitis (MPA)eosinophilic granulomatosis with polyangiitis (EGPA)
Beyond the preview
Go deeper on 2008-004138-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-004138-26.